(S)-N-(8-((2-Amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide
(1) is a potent adaptor-associated kinase 1 inhibitor,
which may have the potential to treat neuropathic pain and other neurological
disorders including schizophrenia, Parkinson’s disease, bipolar
disorder, and Alzheimer’s disease. For preclinical studies,
a substantial amount of high-quality material was required. The original
discovery route for the preparation of this compound suffered from
scale-up issues that included a very low-yielding C–O coupling
step and the use of expensive and toxic reagents. This paper describes
a rapid scale-up synthesis accomplished in eight steps, which involves
the coupling of phenol 17 with oxathiazolidine 18 as the key transformation.